Alessandra M. Silva

A clioquinol-containing Pluronic® F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model

R. J. Alves, D. Menezes-Souza, L. Perin, 2020, Parasite.

Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis

E. S. Coimbra, D. Menezes-Souza, J. Leite, 2020, Parasite immunology.

Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection.

R. Fujiwara, W. F. Siqueira, Lívia M. Carvalho, 2021, Microbial pathogenesis.

Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis.

D. Menezes-Souza, Lívia M. Carvalho, B. M. Roatt, 2020, Molecular immunology.

Recombinant guanosine-5'-triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infection.

B. M. Roatt, Grasiele S. V. Tavares, João A. Oliveira-da-Silva, 2022, Cytokine.

Potential of recombinant LiHyQ, a novel Leishmania infantum protein, for the diagnosis of canine visceral leishmaniasis and as a diagnostic and prognostic marker for human leishmaniasis and human immunodeficiency virus co-infection: a preliminary study.

Grasiele S. V. Tavares, João A. Oliveira-da-Silva, F. Ramos, 2021, Acta tropica.

Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.

E. S. Coimbra, B. M. Roatt, Grasiele S. V. Tavares, 2020, Experimental parasitology.

A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.

Lívia M. Carvalho, B. M. Roatt, Grasiele S. V. Tavares, 2020, Cellular immunology.